Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute Ggaft-versus-host disease but does not improve outcome for advanced hematologic malignancy

被引:33
作者
Levine, JE
Uberti, JP
Ayash, L
Reynolds, C
Ferrara, JLM
Silver, SM
Braun, T
Yanik, G
Hutchinson, R
Ratanatharathorn, V
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Publ Hlth, Blood & Marrow Stem Cell Transplantat Program, Ann Arbor, MI 48109 USA
关键词
reduced-intensity regimen; allogeneic hematopoietic stem cell transplantation;
D O I
10.1053/bbmt.2003.50012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to patients who cannot tolerate fully myeloablative regimens. However, relapse and graft-versus-host disease (GVHD) continue to be major causes of morbidity and mortality. We prospectively tested whether a moderate reduction of the intensity of the preparative regimen would lead to significant reduction in regimen-related toxicity without compromising tumor control in a cohort of 44 patients ineligible for conventional hematopoietic stem cell transplantation. Patients were conditioned with fludarabine, busulfan, mycophenolate, and total lymphoid irradiation. Tacrolimus and methotrexate were given as prophylaxis for GVHD. Donors were 5 of 6 or 6 of 6 matched family members. The median age was 61 years. Eleven patients had comorbid conditions that precluded conventional myeloablative transplantation. Fatal regimen-related organ toxicity occurred in 3 patients. The cumulative incidence of grade 2 to 4 or grade 3 to 4 acute GVHD by day 100 was 38% (95% confidence interval [CI] = 25%, 55%) and 20% (95% CI = 10%, 39%), respectively, with a median time to onset of 66 days. For the entire cohort, 1-year overall survival, disease-free survival, and relapse rates were 54% (95% CI = 41%, 71%),47% (95% CI = 35%, 65%), and 37% (95% CI = 19%, 51%), respectively. Outcomes differed based on stage of disease at time of transplantation, advanced (n = 19) versus nonadvanced (n = 25). Median survival times were 138 days and 685 days for subjects with advanced and nonadvanced disease, respectively (P = .005). After adjusting for age and comorbidity, disease stage continued to be significantly associated with overall survival (P = .005). In conclusion, a moderate reduction in conditioning dose intensity resulted in delayed onset of acute GVHD (compared with historical controls). A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control. (C) 2003 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:189 / 197
页数:9
相关论文
共 23 条
[1]  
ANTIN JH, 1992, BLOOD, V80, P2964
[2]   Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT [J].
Bader, P ;
Beck, J ;
Frey, A ;
Schlegel, PG ;
Hebarth, H ;
Handgretinger, R ;
Einsele, H ;
Niemeyer, C ;
Benda, N ;
Faul, C ;
Kanz, L ;
Niethammer, D ;
Klingebiel, T .
BONE MARROW TRANSPLANTATION, 1998, 21 (05) :487-495
[3]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[4]  
Carella AM, 1998, HAEMATOLOGICA, V83, P904
[5]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[6]   LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation [J].
Cooke, KR ;
Gerbitz, A ;
Crawford, JM ;
Teshima, T ;
Hill, GR ;
Tesolin, A ;
Rossignol, DP ;
Ferrara, JLM .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (12) :1581-1589
[7]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[8]   Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation [J].
Giralt, S ;
Thall, PF ;
Khouri, I ;
Wang, XM ;
Braunschweig, I ;
Ippolitti, C ;
Claxton, D ;
Donato, M ;
Bruton, J ;
Cohen, A ;
Davis, M ;
Andersson, BS ;
Anderlini, P ;
Gajewski, J ;
Kornblau, S ;
Andreeff, M ;
Przepiorka, D ;
Ueno, NT ;
Molldrem, J ;
Champlin, R .
BLOOD, 2001, 97 (03) :631-637
[9]   Transplant-lite:: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies [J].
Khouri, IF ;
Keating, M ;
Körbling, M ;
Przepiorka, D ;
Anderlini, P ;
O'Brien, S ;
Giralt, S ;
Ippoliti, C ;
von Wolff, B ;
Gajewski, J ;
Donato, M ;
Claxton, D ;
Ueno, N ;
Andersson, B ;
Gee, A ;
Champlin, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2817-2824
[10]   Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease [J].
Krijanovski, OI ;
Hill, GR ;
Cooke, KR ;
Teshima, T ;
Crawford, JM ;
Brinson, YS ;
Ferrara, JLM .
BLOOD, 1999, 94 (02) :825-831